Searched for
ASTRAZENECA PHARMA SHARES
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...
- Breakout Stocks: How Ujjivan SFB, Godrej Industries and AstraZeneca Pharma are looking on charts for Monday’s tradeWe have collated a list of three stocks that either hit a fresh 52-week high, or all-time high or saw a volume or a price breakout.We spoke...
- Chart Check: AstraZeneca Pharma gives breakout from 7-month consolidation phase; where is the stock headed?Experts predict that AstraZeneca Pharma's stock price may hit 4000 levels in the next month after breaking out from a 7-month-long consolid...
- AstraZeneca Pharma gains despite fall in Q2 profit; here's whyIn the July-September quarter, AstraZeneca Pharma India reported a decline of 54.65 per cent in net profit to Rs 11.94 crore. In the same p...
- AstraZeneca Pharma gets DCGI nod to market asthma drugAstraZeneca Pharma said the receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India, subject to the receipt ...
- AstraZeneca Pharma India Q1 results: Net profit declines 13% at Rs 18.63 croreDrug firm AstraZeneca Pharma India on Monday reported a 13.38 per cent decline in its net profit to Rs 18.63 crore for the quarter ended Ju...
- AstraZeneca Pharma India gets DCGI nod to market diabetes drugThe product is indicated as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes, AstraZeneca...
- AstraZeneca Pharma India appoints Gagan Singh Bedi as MDThe company has accepted resignation of Sanjay Murdeshwar as MD and as a director. He is shifting to a global role within the AstraZeneca g...
- AstraZeneca Pharma India to close Bengaluru API unitDrug firm AstraZeneca Pharma India will close its Active Pharmaceutical Ingredient (API) unit at Bengaluru due to low demand for the produc...
- AstraZeneca Pharma board approves delisting of company's shares from stock exchangesAstraZeneca Pharma today said its board has approved delisting of the company's shares from bourses, including BSE and the National Stock E...
- AstraZeneca Pharma shares rise 3 per cent on board's approved delisitngShares of AstraZeneca Pharma rose by 3 per cent as its board has approved delisting of the company's shares from bourses like NSE, BSE etc.
- Buy AstraZeneca Pharma Ltd with target price of Rs 1020: Sandeep WagleAstraZeneca Pharma Ltd is a 'BUY' call with a target of Rs 1020 and a stop loss of Rs 884.
- AstraZeneca up 20% on delisting proposal, locked in upper circuit at Rs 1,110.90AstraZeneca said in the filing before markets opened on Monday that its board received a request from its promoter to initiate a voluntary ...
- Buy AstraZeneca Pharma India Ltd with a target of Rs 870: Ashwani Gujral"AstraZeneca Pharma India Ltd is a ‘BUY’ call with a target of Rs 870 and a stop loss of Rs 825."
- Buy AstraZeneca Pharma with target price of Rs 930: Ashwani GujralAstraZeneca Pharma Ltd is a 'BUY' call with a target of Rs 930 and a stop loss of Rs 850.
- Buy Astrazeneca Pharma with target price of Rs 960: Prakash GabaBuy Astrazeneca Pharma at a stop of Rs 807.
- AstraZeneca Pharma promoter to sell stake in Indian armAstraZeneca India today said its promoter AstraZeneca Pharmaceuticals AB Sweden plans to offload around 37 lakh shares through offer for sa...
- Buy AstraZeneca Pharma with a target of 1860: Sandeep WagleAstraZeneca Pharma India Ltd is a ‘BUY’ call with a target of Rs 1860 and a stop loss of Rs 1680.
- AstraZeneca Pharma to delist from India; shares jump 20 pcAstraZeneca Pharma India today said it will de-list itself from domestic stock exchanges, fueling a jump of 20 per cent in its stock price ...
Load More
